Vangest has completed the acquisition of Micro Systems Ltd and Optimold Limited, strengthening its international expansion with new production units in the United Kingdom and Singapore.
The company did not disclose the value of the transactions involving the two leading British manufacturers in medical molds and injection molding, but stated the investment was made with its own capital, without resorting to debt, emphasizing Vangest as one of the financially solid companies in the sector.
This expansion bolsters the company headquartered in Marinha Grande, Leiria district, enhancing its innovation capacity with faster development cycles and greater proximity to global clients, focusing on manufacturing for critical health and medical technology sectors.
Since the pandemic, Vangest has been acquiring other companies, doubling its number of highly specialized staff from 250 to 500. This acquisition follows the purchase of Spain’s Tecnomatrix in 2024, consolidating Vangest’s European presence, according to a press release.
“The group now offers a broader portfolio in advanced diagnostic devices, ophthalmological products, drug delivery systems, and other critical medical technologies,” reinforcing “its position as a strategic partner,” the press release highlights.
Micro Systems Ltd and Optimold Limited, experts in high-precision molds and injection molding for the medical industry, are now fully integrated into the group, which has production facilities in Portugal, Spain, the UK, and Singapore.
“With the acquisition of Micro Systems and Optimold, we have taken another crucial step as a global player in molds and injection molding for the medical industry,” stated Vangest’s Chairman of the Board, Kees Verhaar.
According to the CEO, Jarl Severn, “these strategic acquisitions expedite development cycles, enhance operational agility, and offer clients shorter delivery times, regional proximity, and a broader portfolio of engineering and manufacturing services.”
Vangest reported a turnover of 43 million euros in 2024, estimating to reach between 65 and 70 million this year.
With the transition from automotive mold manufacturing in decline, the company is growing in the medical field, representing about 50% of the group’s business, with a trend toward strengthening the aerospace and defense sectors.
Vangest heads a consortium of companies in the sector, recipient of a 104 million euro financing from the Recovery and Resilience Plan (PRR), with all deadlines met, as informed.
Founded in 1986 and based in Portugal, the Vangest group is a European leader in integrated engineering and manufacturing solutions, with operations in Portugal, the UK, Spain, and Singapore, the release states.
The group operates 11 specialized factories, with 65,000 square meters of industrial area and over 500 employees.
Its portfolio covers the entire product lifecycle—from design, prototyping, and engineering to high-precision mold production, thermoplastics injection molding, and assembly—serving the medical, industrial, and aerospace sectors.
